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Summary
Hemoglobin breakdown produces an iron-dependent neuronal injury after
experimental CNS hemorrhage that may be attenuated by heme oxygenase (HO)
inhibitors. The HO enzymes are phosphoproteins that are activated by phosphorylation
in vitro. While testing the effect of kinase inhibitors in cortical cell cultures, we observed
that HO activity was consistently decreased by the MEK inhibitor U0126. The present
study tested the hypothesis that MEK/ERK pathway inhibitors reduce HO activity and
neuronal vulnerability to hemoglobin. The MEK inhibitors U0126 and SL327 and the
ERK inhibitor FR180204 reduced baseline culture HO activity by 35-50%, without
altering the activity of recombinant HO-1 or HO-2; negative control compounds U0124
and FR180289 had no effect. Hemoglobin exposure for 16 hours produced widespread
neuronal injury, manifested by release of 59.2±7.8% of neuronal lactate dehydrogenase
and a twelve-fold increase in malondialdehyde; kinase inhibitors were highly protective.
HO-1 induction after hemoglobin treatment was also decreased by U0126, SL327, and
FR180204. These results suggest that reduction in HO activity may contribute to the
protective effect of MEK and ERK inhibitors against heme-mediated neuronal injury.

Key Words: cell culture; free radical; hemoglobin toxicity; intracerebral hemorrhage;
mouse; oxidative stress
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Introduction
A considerable body of experimental and clinical evidence suggests that toxins
released from an intracerebral hematoma may contribute to cell injury in adjacent tissue
(Xi, et al., 2006). One putative neurotoxin is hemoglobin, the most abundant protein in
blood, which is released from lysed erythrocytes in the days after hemorrhage and
contributes to peri-hematomal edema and oxidative stress (Huang, et al., 2002).
Investigation of hemoglobin neurotoxicity in cell culture models and in vivo suggests that
the hemoglobin molecule per se is not the primary toxin (Sadrzadeh, et al., 1987, Regan,
et al., 1993). However, at least under some experimental conditions, the quantity of iron
released as a consequence of the breakdown of its heme moieties apparently exceeds the
sequestration or export capacity of CNS cells. The result is an injury that is largely
selective for neurons, which are highly sensitive to low molecular weight iron (Kress, et
al., 2002).
Heme degradation to equimolar quantities of iron, biliverdin, and carbon
monoxide is catalyzed by the heme oxygenase (HO) enzymes (Abraham, et al., 2008).
Two isoforms have been identified to date in the mammalian CNS (Schipper, 2004).
Heme oxygenase-1 is expressed primarily by glial cells and is induced by heat shock,
heme, and a variety of oxidants. Heme oxygenase-2 is constitutively expressed by
neurons and endothelial cells. The effect of heme oxygenase activity on acute CNS
injury has been extensively investigated in studies using either HO inhibitors or
genetically modified mice. A protective effect has been consistently observed in models
that are relevant to ischemia or trauma (Takizawa, et al., 1998, Panahian, et al., 1999,
Chang, et al., 2003), which has been attributed to the antioxidant and anti-inflammatory
effects of biliverdin/bilirubin and carbon monoxide (Abraham, et al., 2008, Parfenova, et
al., 2008). In contrast, HO activity increased or accelerated injury in most (Wagner, et
al., 2000, Koeppen, et al., 2002, Koeppen, et al., 2004, Gong, et al., 2006, Wang, et al.,
2006a, Qu, et al., 2007) but not all (Wang, et al., 2006b) experimental models of
intracerebral hemorrhage (ICH), presumably due to iron toxicity that negated any benefit
of the other breakdown products.
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Clinical ICH is a complex injury that may include varying degrees of compressive
ischemia, mechanical injury from hematoma expansion or retraction, inflammation, and
the toxicity of blood components (Xi, et al., 2006). The disparate effect of HO on hememediated and other CNS injuries suggests that it may be a challenging therapeutic target,
since any benefit of direct HO inhibitors against hemoglobin neurotoxicity may be
negated by their deleterious effects on other injury cascades. An alternative approach to
direct enzyme inhibition is to prevent the increase in HO activity produced by
hemorrhage, which may be due to HO activation and/or HO-1 induction. Both HO-1 and
HO-2 are phosphoproteins, and in vitro are activated by the phosphatidylinositol-3-kinase
and protein kinase C/CK2 pathways, respectively (Boehning, et al., 2003, Salinas, et al.,
2004). However, we have recently observed that selective inhibitors of these pathways
had no effect on HO activity in murine cortical cell cultures (Chen-Roetling, et al., 2008).
In the course of these kinase inhibitor experiments, we noted that the MEK 1/2 inhibitor
U0126 surprisingly reduced baseline culture HO activity. In the present study, we tested
the effect of MEK and ERK inhibitors on HO activity and hemoglobin neurotoxicity in
this culture system.

Methods
Cortical cell cultures. All procedures on animals were conducted in accordance with a
protocol approved by the Thomas Jefferson University Institutional Animal Care and Use
Committee (IACUC). Mixed neuron–glia cortical cell cultures were prepared from fetal
B6129 mice (gestational age 13- to 15-days), using a previously described protocol
(Rogers, et al., 2003). After cell dissociation by trituration, cultures were plated on
confluent glial feeder cultures in 24-well plates (Falcon, Becton Dickinson, Franklin
Lakes, NJ), at a density of three hemispheres/plate. Plating medium contained Minimal
Essential Medium (MEM, Invitrogen, Carlsbad, CA), 5% equine serum (Hyclone, Logan,
UT), 5% fetal bovine serum (Hyclone), 23 mM glucose, and 2 mM glutamine. On day 5
in vitro, two-thirds of the culture medium was aspirated and replaced with feeding
medium, which was similar to plating medium except that it contained 10% equine serum
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and no fetal bovine serum. This procedure was repeated on day 9 or 10 and then daily
beginning on day 11. Glial feeder cultures were prepared from postnatal day 1-3 mice,
using plating medium similar to that described above, except that it was supplemented
with 10 ng/ml epidermal growth factor (Sigma, St. Louis, MO), 10% equine serum and
10% fetal bovine serum. Glial culture medium was partially changed twice weekly.

MEK/ERK pathway inhibitors and negative controls. U0126 (Promega, Madison, WI) is
a potent inhibitor of both MEK1 and MEK2 (Favata, et al., 1998). It differs from the
commonly-used MEK inhibitor PD98059 by directly inhibiting MEK enzyme activity,
rather than by preventing its activation by Raf, and also by having much greater activity
against MEK2 (Alessi, et al., 1995). U0124 (Tocris Bioscience, Ellisville, Missouri) is a
similar compound that does not inhibit MEK, and is marketed as a negative control.
SL327 (Tocris) also selectively inhibits both MEK1 and MEK 2 (Scherle, et al., 2000).
FR180204 (EMD/Calbiochem, San Diego, CA) is inactive against MEK, but directly
inhibits ERK1 (MAPK3) and ERK2 (MAPK3(Ohori, et al., 2005). FR180289 (EMD)
differs from FR180204 only by substitution of a hydroxyl group for the 3' amine (Ohori,
et al., 2005), but does not inhibit ERK1 or ERK2 and is marketed as its negative control.

HO activity assay. HO activity was quantified using a modification of the method of
Vreman and Stevenson (Vreman, et al., 1988). Concentrated inhibitor stock solutions
were freshly prepared in dimethylsulfoxide (DMSO). Dilutions were adjusted so that all
conditions including sham-wash controls and hemoglobin without inhibitors had the same
DMSO concentration (0.25%). Cultures were treated for either 30 minutes or 4 hours
with enzyme inhibitors, hemoglobin, or both in MEM containing 10 mM glucose
(MEM10) at 37oC in a 5% CO2 incubator; control cultures received MEM10 with DMSO
vehicle only. At the end of the exposure interval, cultures were washed and harvested in
ice-cold Dulbecco’s Phosphate Buffered Saline (DPBS) with 3X concentration of
inhibitors or DMSO vehicle. Samples of the cell suspension (40 µl) were placed in
amber septum-sealed glass vials on ice, and were diluted with equal volumes of freshly
prepared 75 µM hemin and 4.5 mM NADPH (final reactant concentrations 25 µM hemin,
1.5 mM NADPH, total volume 120 µl); control vials lacked NADPH. Vials were purged
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for 4 sec with CO-free air at a flow rate of 250 ml/min. Reactions were then run for 15
minutes at 37oC in a water bath under reduced light, and were terminated by quickfreezing vials on dry ice. CO was quantified in the vial head space by gas
chromatography (Peak Laboratories, Mountain View, CA). HO activity was expressed as
nanomoles CO produced per hour per milligram protein. Protein concentrations were
determined by the BCA method (Pierce, Rockford, IL).
Immunoblotting. Cells were lysed in ice-cold lysis buffer (210 mM mannitol, 70 mM
sucrose, 5 mM HEPES, 1 mM EDTA, 0.1 % sodium dodecyl sulfate, 0.1 % Triton X100). After sonication, debris was removed by centrifugation, and the protein
concentration of the supernatant was quantified (BCA method, Pierce, Rockford, IL).
Samples (20 µg protein each) were then boiled in sample buffer (Tris-Cl 60 mM, βmercaptoethanol 5%, sodium dodecyl sulfate 2%, glycerol 10%, and bromophenol blue
0.05%) for 3 min. Proteins were separated on 12 % SDS polyacrylamide gels at 80–100
V. The gels were then soaked in transfer buffer (glycine 39mM, Tris-CL 48mM, SDS
0.037% and methanol 20%), and were transferred to polyvinylidene difluoride
membranes with a semidry transfer apparatus for 40 minutes at 20V. Completion of
transfer was assessed by observing the transfer of the pre-stained protein marker (BioRad Laboratories, Hercules, CA, Cat. No. 161-0375). After blocking with 5% nonfat dry
milk, membranes were exposed overnight at 4 °C to rabbit anti-HO-1 or anti-HO-2
antibodies (Assay Designs, Ann Arbor, MI, 1:5000 and 1:2000 dilutions, respectively)
combined with rabbit anti-actin antibody (1/1500, Sigma, St. Louis, MO ) as a gel
loading control. After washing, they were then exposed to HRP-conjugated goat antirabbit IgG antibody (1:3500) for 1h at room temperature. Immunoreactive proteins were
visualized using Super Signal West Femto Reagent (Pierce) and Kodak Gel Logic 2200.
Immunocytochemistry. Cultures were washed with MEM10 and then fixed with ice-cold
4% paraformaldehyde for one hour. After washing with tris-buffered saline (TBS),
cultures were serially treated with: 0.25% Triton X-100 for 10 min, 10% normal goat
serum for 15 min, 1:100 dilutions of primary antibodies (anti-NeuN, clone A60, Alexa
Fluor®488 conjugated, Millipore, Billerica, MA or rabbit anti-glial fibrillary acidic
protein (GFAP), Invitrogen, Carlsbad, CA) overnight. Cultures treated with anti-NeuN

6

were then washed and imaged. Cultures treated with anti-GFAP were treated for 30 min
with biotinylated anti-rabbit IgG (1:200, Vector Laboratories, Burlingame, CA) followed
by NeutrAvidin Rhodamine Red-X conjugate (Invitrogen) 5 µg/ml for 30 min.
ERK activity assay. The effect of inhibitors and negative controls was confirmed using
the p44/42 MAP Kinase assay kit (Cell Signaling Technology, Danvers, MA), following
the manufacturer's instructions.

Cell lysates were incubated overnight at 4oC with

immobilized phospho-p44/42 ERK monoclonal antibody. Immunoprecipitation pellets
were then collected by centrifugation and were incubated in kinase buffer containing
substrate (Elk-1 fusion protein) and 200 µM ATP at 30oC for 30 minutes.
Phosphorylated Elk-1 was detected by immunoblotting as described above, using a
1:1000 dilution of rabbit anti-phospho-Elk (Ser 383) primary antibody.
Cytotoxicity experiments. Cultures were used for experiments on 12-16 days in vitro.
Neurons are easily distinguished from glial cells during this interval by their phase-bright
cell bodies and extensive network of processes. All exposures were conducted in
MEM10 at 37oC in a 5% CO2 atmosphere. As described above, the dilution of all
inhibitors was adjusted so that all conditions contained 0.25% DMSO vehicle. Control
cultures in each experiment were subjected to medium exchange only, following which
they were treated with an equal concentration of DMSO vehicle. The hemoglobin
exposure concentration was determined from prior studies using this model, which
demonstrated that 10 µM hemoglobin (tetramer concentration) produced widespread
neuronal injury with overnight treatment (Rogers, et al., 2003), without injuring
astrocytes (Chen-Roetling, et al., 2006).

Assessment of injury. Neuronal death was quantified by assaying lactate dehydrogenase
(LDH) activity in the culture medium, a method that correlates well with cell counts after
trypan blue staining in mixed cortical cultures (Koh, et al., 1988), as previously described
(Regan, et al., 1998). In order to compare results from experiments using cultures
prepared in different platings, all LDH values were normalized to those in sister cultures
from the same plating treated with 300 µM NMDA, which releases virtually all neuronal
LDH without injuring glial cells. The mean baseline LDH activity of sister cultures
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subjected to medium exchange and vehicle treatment only was subtracted from all values
to quantify the signal that was specific to the cytotoxic exposure, following the protocol
of Koh and Choi (Koh, et al., 1988).
Malondialdehyde is a sensitive marker of oxidative injury in this model (Regan, et
al., 1998). After sampling for LDH assay, cultures were harvested, proteins were
precipitated with 4.5% trichloroacetic acid, and malondialdehyde was quantified as
previously detailed (Regan, et al., 1998). Protein content of each sample was estimated
by the BCA method (Pierce, Rockford, IL); all malondialdehyde values were expressed
as nanomoles/milligram protein.
Statistical Analysis. Data were analyzed with one-way analysis of variance. Differences
between groups were then assessed with the Bonferroni Multiple Comparisons test.

Results
MEK and ERK inhibitors attenuate culture HO activity. In initial experiments, the effect
of 30 min incubation with MEK or ERK inhibitors on culture HO activity was assessed.
HO activity in control cultures treated with DMSO vehicle only for this interval was
1.01±0.07 nmol CO/h/mg protein (Fig. 1A). In cultures treated with the MEK inhibitors
U0126 or SL327 or the ERK inhibitor FR180204, a significant reduction in HO activity
was observed. U0124 and FR180289, structural analogs of U0126 and FR180204 that
are marketed as negative controls for these compounds, had no effect on HO activity at
the same concentrations. Kinase activity assays confirmed that, at the concentrations
used, U0126, SL327, and FR180204 inhibited phosphorylation of Elk-1 by ERK, while
U0124 and FR180289 had no such effect (Fig. 1B, C).
In order to determine if these MEK and ERK inhibitors were direct HO inhibitors,
their effect on the activity of recombinant HO-1 and HO-2 (both purchased from Assay
Designs, Ann Arbor, MI) was determined. In the presence of DMSO vehicle only,
recombinant HO-1 and HO-2 had activities of 297.0±39.0 nmol CO/h/mg protein and
504.2±44.1 nmol CO/h/mg protein, respectively (Fig. 2). These activities were not
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significantly altered by U0126, SL327, or FR180204. Not surprisingly, the activity of
both recombinant isoenzymes was strongly inhibited by the HO inhibitor zinc
protoporphyrin IX (50 µM).

MEK and ERK inhibitors protect neurons from hemoglobin. We have previously
reported that reducing HO activity by either HO-2 gene knockout or treatment with an
HO inhibitor protects neurons in this culture system from hemoglobin (Rogers, et al.,
2003). Since MEK and ERK inhibitors rapidly reduced HO activity, their effect on
hemoglobin neurotoxicity was assessed. Consistent with prior observations, widespread
neuronal injury was observed in cultures treated for 16h with 10 µM hemoglobin plus
DMSO vehicle only (Fig. 3); the glial monolayer remained intact and morphologically
normal throughout the course of the experiment, also as previously reported (ChenRoetling, et al., 2006). Cell death, as quantified by LDH release into the culture medium,
was 59.2±7.8% of that in sister cultures treated with 300 µM NMDA, which releases
essentially all neuronal LDH (Fig. 4A). Concomitant treatment with U0126, SL327, or
FR180204 consistently had a robust protective effect (Fig. 3, 4A).

MEK and ERK inhibitors reduce expression of oxidative injury markers after hemoglobin
treatment. Malondialdehyde is a sensitive marker of the oxidative injury produced by
hemoglobin in CNS cells (Sadrzadeh, et al., 1987). In cultures treated with hemoglobin
plus vehicle only, it was increased by 12.5-fold compared with control cultures subjected
to medium exchange and vehicle treatment only (Fig. 4B). Malondialdehyde levels in
cultures treated with hemoglobin plus kinase inhibitors were similar to those in vehicletreated controls.
HO-1 is rapidly induced by oxidants in CNS cells (Schipper, 2004). Since MEK
and ERK inhibitors appeared to be acting as antioxidants in this model, their effect on
HO-1 expression was determined. In cultures treated with hemoglobin plus DMSO
vehicle for 4h, which is a time point prior to the onset of neuronal lysis, HO-1 expression
was increased 2.2-fold over control cultures treated with vehicle only (Fig. 5A).
Consistent with prior observations (Benvenisti-Zarom, et al., 2006), this increase was
reduced by about half by U0126 and SL327, and was completely prevented by the direct
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ERK inhibitor FR180204. HO-2 expression was not altered by hemoglobin or kinase
inhibitor treatment. HO activity was increased approximately 2.5-fold by hemoglobin
(Fig. 5B). This increase was completely prevented by concomitant treatment with
U0126, SL327, or FR180204.

Discussion
These results suggest the following conclusions. First, baseline HO activity is
attenuated by inhibitors of the MEK/ERK pathway in this mixed neuron/glia cell culture
system. Second, this decrease is associated with reduced neuronal vulnerability to
hemoglobin, in agreement with prior observations that HO activity accelerates
hemoglobin neurotoxicity in cell culture and in vivo (Huang, et al., 2002, Rogers, et al.,
2003). Third, HO-1 induction in this hemoglobin neurotoxicity model is also reduced by
these inhibitors, suggesting that it is mediated at least in part by the MEK/ERK signal
transduction pathway.
The inhibition in HO activity after brief incubation with ERK or MEK inhibitors
was unexpected, since activation of HO-1 or HO-2 by ERK-catalyzed phosphorylation
has not been reported. HO-1 has possible ERK phosphorylation sites at T108, S174, and
T252, and an ERK1 binding site at P170, while HO2 has several ERK docking domain
sites (Obenauer, et al., 2003). The effect of ERK-catalyzed phosphorylation on HO
activity has not been defined and seems worthy of further investigation. It is unlikely that
the inhibitors acted directly on HO catalysis, since they had no significant effect on the
activity of recombinant HO-1 or HO-2. In assessing these compounds in oxidative injury
models, the potentially confounding effect of reduced HO activity should be considered.
The protective effect of MEK and ERK inhibitors provides an additional line of
evidence that excessive HO activity may be detrimental to neurons exposed to
hemoglobin, and complements prior and more specific observations using HO-2
knockout neurons or HO inhibitors (Huang, et al., 2002, Rogers, et al., 2003). A growing
body of experimental evidence suggests that HO activity may have either antioxidant or
pro-oxidant effects, with the net effect varying with the cell population and the type of
10

injury. Two factors may account for a pro-oxidant effect in this hemoglobin
neurotoxicity model. First, HO substrate was added to cultures at a relatively high
concentration (10 µM hemoglobin, containing 40 µM heme). While this concentration is
considerably lower than that adjacent to an intracerebral hemorrhage (Letarte, et al.,
1993), it is markedly higher than the endogenous heme that is available to cells in models
more relevant to CNS ischemia (~ 1 nM, Taketani, 2005), in which HO activity is
protective (Takizawa, et al., 1998, Panahian, et al., 1999). Second, neurons are very
vulnerable to low molecular weight iron (Kress, et al., 2002), a product of heme
breakdown by HO, which likely reflects their limited capacity to sequester it in ferritin
(Moos, et al., 2004). Release of supraphysiologic quantities of iron may overwhelm any
benefit provided by HO activity (Dennery, et al., 2003), which includes bilirubin and
carbon monoxide production (Abraham, et al., 2008, Parfenova, et al., 2008).
In addition to reducing HO activity, several other mechanisms may contribute to
the robust neuroprotection provided by U0126, SL327, and FR180204 in this model.
Activation of the MEK/ERK pathway may mediate neuronal injury in an oxidative
environment by directly activating calpain (Glading, et al., 2000), phospholipase A2
(Geijsen, et al., 2000), and NADPH oxidase (Dewas, et al., 2000), and also by increasing
production of inflammatory cytokines (Wang, et al., 2004). In addition, ERK signaling
mediates apoptosis in CNS cells by upregulating Bax and p53 while downregulating Akt
(Zhuang, et al., 2006). Although the association of reduced HO activity and neuronal
resistance to hemoglobin is consistent with prior observations using more specific
approaches (Huang, et al., 2002, Rogers, et al., 2003), the downstream mechanistic
information provided by inhibiting the MEK/ERK pathway is limited by the myriad
effects of ERK signaling.
We have previously reported that HO-1 is expressed at a low level in primary
cultured neurons and glia, and that it is rapidly induced in glia by hemoglobin or hemin
treatment (Regan, et al., 2000, Benvenisti-Zarom, et al., 2006). In contrast to the effect
of HO on neurons, HO-1 expression protects glial cells from hemoglobin (Regan, et al.,
2000, Chen-Roetling, et al., 2006). Prolonged hemoglobin treatment produces no injury
in glial cultures prepared from wild-type mice, but widespread cell death in HO-1
knockout cultures (Chen-Roetling, et al., 2006), and also in wild-type cultures treated
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concomitantly with HO inhibitors (Regan, et al., 2000). In the present study, the glial
feeder monolayer remained morphologically normal after treatment with hemoglobin
plus MEK or ERK inhibitors despite a reduction in culture HO-1 expression and HO
activity. Immunostaining demonstrated that most of these glial cells were astrocytes;
however, a low level of microglial contamination cannot be excluded (Saura, 2007), and
may have contributed to neuronal injury in this model. The disparate effect of direct HO
inhibitors and MEK/ERK inhibitors on astrocyte vulnerability to hemoglobin suggests
that astrocytes treated with the latter have sufficient residual HO activity to prevent
hemoglobin-mediated injury. Alternatively, MEK and ERK inhibitors may antagonize
other ERK-activated injury cascades in astrocytes, and thereby compensate for the
deleterious effect of reduced HO activity in this cell population.
MEK/ERK pathway inhibitors have been extensively tested in small animal
models of CNS ischemia and trauma, and have been found to reduce lesion volume and
neurological deficits (Namura, et al., 2001, Wang, et al., 2003, Clausen, et al., 2004,
Wang, et al., 2004, Otani, et al., 2007). However, comparable studies have not yet been
reported in intracerebral hemorrhage models. The results of the present study suggest
that U0126, SL 327, and FR180204 may ameliorate the component of injury produced by
the breakdown of extracellular hemoglobin in tissue surrounding an intracerebral
hematoma. Investigation of these compounds in vivo therefore seems warranted.
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Figure Legends
Figure 1. MEK and ERK inhibitors reduce culture heme oxygenase (HO) activity.
A) Mean HO activity (nmol CO/h/mg protein ±SEM, n = 5-12/condition) in cultures
washed and then treated with DMSO vehicle only (Veh) or with U0126 (30 µM), SL327
(30 µM), FR180204 (FR, 50 µM), U0124 (negative control for U0126, 30 µM), or
FR180289 (FRN, negative control for FR180204, 50 µM) for 30 minutes. ***P<0.001
and **P<0.01 v. activity in vehicle-treated cultures, Bonferroni multiple comparisons
test. B) Immunoblot demonstrating effect of MEK inhibitors and negative control U0124
on kinase activity at these concentrations, as assessed by phosphorylation of ERK
substrate Elk-1. Cultures were treated with hemoglobin (Hb) 10 µM alone or with
inhibitors or control for 4 hours before lysis and immunoprecipation of active ERK for
kinase assay. C) Immunoblot demonstrating inhibition of active ERK by FR180204 (FR,
50 µM) but not by FR180289 (FRN, 50 µM).

Figure 2. Effect of MEK and ERK inhibitors on activity of recombinant HO-1 and HO-2.
HO activity of recombinant rat HO-1 and HO-2 with DMSO vehicle alone (Veh) or with
U0126 (30 µM), SL327 (30 µM), FR180204 (FR, 50 µM), or zinc protoporphyrin IX
(ZnPPIX, 50 µM). Reaction vial contained 0.25µg cytochrome P450 reductase with 2.5
µg HO-1 or 1 µg HO-2. **P<0.01, **P<0.001 v. corresponding vehicle condition,
Bonferroni multiple comparisons test.

Figure 3. Morphologic appearance of mixed neuron-astrocyte cultures 24h after: A, C, E)
Treatment with vehicle only. Neurons with phase-bright cell bodies appear primarily in
clusters on the glial feeder layer monolayer, which is in a different plane and therefore
slightly out of focus. Phase-bright cells stain with Alexa Fluor®488 conjugated antiNeuN (C), confirming neuronal identity, while background glial monolayer stains with
anti-GFAP (E). B, D, F) Treatment with hemoglobin 10 µM with vehicle. Most neurons
have degenerated to debris, astrocyte monolayer is intact (B), NeuN immunoreactivity is
diminished and limited to areas of degenerating cells (D), GFAP immunoreactivity
persists and is increased, particularly near degenerating neurons (E). G, H) Unfixed
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cultures treated with hemoglobin 10 µM plus U0126 (30 µM) or FR180204 (50 µM),
respectively; neuronal morphology is preserved. Scale bar = 100 µm.

Figure 4. MEK and ERK inhibitors protect neurons from hemoglobin. A) Cultures were
treated for 16h with hemoglobin (Hb) 10 µM plus DMSO vehicle alone or with U0126
(30 µM), SL327 (30 µM), or FR180204 (FR, 50 µM). LDH values are scaled to mean
values in sister cultures treated with 300 µM N-methyl-D-aspartate (NMDA), which
produces near-100% neuronal death, after subtraction of mean LDH in sister cultures
subjected to wash and vehicle treatment only, in order to yield the LDH signal specific
for hemoglobin neurotoxicity. B) Culture malondialdehyde (MDA) after treatment as in
A. ***P<0.001. v. Hb, Bonferroni multiple comparisons test, n = 8-23/condition.

Figure 5. MEK and ERK inhibitors prevent HO-1 induction after hemoglobin treatment.
A) Expression of HO-1, HO-2 and actin (gel loading control) in cultures treated with
vehicle (Veh) only for 4h, with hemoglobin (Hb) 10 µM plus vehicle, or with Hb plus
U0126 (30 µM), SL327 (30 µM), or FR180204 (FR, 50 µM). B) HO activity in cultures
treated as in A. ###P<0.001. v. vehicle, *P<0.05, **P<0.01, ***P<0.001 v. Hb,
Bonferroni multiple comparisons test, n = 5-13/condition.
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